Susquehanna International Group, LLP Alkermes Plc. Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2025

A detailed history of Susquehanna International Group, LLP transactions in Alkermes Plc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 232,025 shares of ALKS stock, worth $6.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

232,025

Previous 115,707 100.53%

Holding current value

$6.75 Million

Previous $3.33 Million 130.27%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$28.08 - $36.0 $3.27 Million - $4.19 Million	116,318 Added 100.53%	232,025 $7.66 Million
Q4 2024 Feb 14, 2025	SELL	$25.7 - $31.46 $953,572 - $1.17 Million	-37,104 Reduced 24.28%	115,707 $3.33 Million
Q3 2024 Nov 14, 2024	BUY	$23.01 - $28.55 $2.87 Million - $3.56 Million	124,527 Added 440.27%	152,811 $4.28 Million
Q2 2024 Aug 15, 2024	SELL	$23.21 - $27.24 $1.41 Million - $1.65 Million	-60,549 Reduced 68.16%	28,284 $681,000
Q1 2024 May 07, 2024	BUY	$26.4 - $32.56 $12,672 - $15,628	480 Added 0.54%	88,833 $2.4 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $17.3 Million - $21.2 Million	-739,527 Reduced 89.33%	88,353 $2.45 Million
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $16.4 Million - $19.3 Million	605,043 Added 271.52%	827,880 $23.2 Million
Q2 2023 Aug 11, 2023	SELL	$28.34 - $33.63 $2.26 Million - $2.69 Million	-79,921 Reduced 26.4%	222,837 $6.97 Million
Q1 2023 May 16, 2023	BUY	$25.31 - $29.02 $4.58 Million - $5.26 Million	181,141 Added 148.94%	302,758 $8.53 Million
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $601,616 - $719,527	-27,421 Reduced 18.4%	121,617 $3.18 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $2.73 Million - $3.95 Million	123,960 Added 494.3%	149,038 $3.33 Million
Q2 2022 Aug 15, 2022	SELL	$26.4 - $30.54 $1.11 Million - $1.28 Million	-42,012 Reduced 62.62%	25,078 $747,000
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $1.55 Million - $1.88 Million	67,090 New	67,090 $1.77 Million
Q3 2021 Nov 15, 2021	SELL	$23.37 - $32.13 $4.07 Million - $5.6 Million	-174,216 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$18.78 - $25.15 $2.5 Million - $3.34 Million	-132,866 Reduced 43.27%	174,216 $4.27 Million
Q1 2021 May 17, 2021	BUY	$18.21 - $23.2 $1.38 Million - $1.76 Million	75,966 Added 32.87%	307,082 $5.74 Million
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $299,289 - $429,778	19,447 Added 9.19%	231,116 $4.61 Million
Q3 2020 Nov 16, 2020	BUY	$16.16 - $20.66 $40,206 - $51,402	2,488 Added 1.19%	211,669 $3.51 Million
Q2 2020 Aug 14, 2020	BUY	$13.31 - $19.41 $2.15 Million - $3.14 Million	161,861 Added 342.06%	209,181 $4.06 Million
Q1 2020 May 15, 2020	SELL	$13.06 - $21.24 $530,719 - $863,129	-40,637 Reduced 46.2%	47,320 $682,000
Q4 2019 Feb 14, 2020	BUY	$17.29 - $21.74 $248,180 - $312,055	14,354 Added 19.5%	87,957 $1.79 Million
Q3 2019 Nov 14, 2019	SELL	$19.51 - $24.28 $502,753 - $625,671	-25,769 Reduced 25.93%	73,603 $1.44 Million
Q2 2019 Aug 16, 2019	BUY	$21.47 - $37.33 $703,979 - $1.22 Million	32,789 Added 49.25%	99,372 $2.24 Million
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $1.18 Million - $2.06 Million	55,100 Added 479.84%	66,583 $1.5 Million
Q2 2018 Aug 14, 2018	SELL	$40.56 - $51.36 $729,066 - $923,196	-17,975 Reduced 61.02%	11,483 $473,000
Q1 2018 May 15, 2018	SELL	$53.61 - $67.26 $8.73 Million - $11 Million	-162,808 Reduced 84.68%	29,458 $1.71 Million
Q4 2017 Feb 14, 2018	BUY	$47.69 - $55.39 $9.17 Million - $10.6 Million	192,266	192,266 $10.5 Million

Others Institutions Holding ALKS

# of Institutions

410

Shares Held

177M

Call Options Held

229K

Put Options Held

436K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.78B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Alkermes Plc. Transaction History